3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Breast Neoplasms
3
Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Advanced Malignancies
2
Urothelial Cancer
1
Thyroid Neoplasms
1
Solid Tumors, KRAS Mutation
1
Sarcoma, Synovial
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Prostatic Neoplasms
1
Prostate Cancer Metastatic
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Opioid-Related Disorders
1
Lung Neoplasms
1
Liposarcoma
1
Leukemia, Myeloid, Acute
1
Leukemia, Biphenotypic, Acute
1
Leukemia
1
Leiomyosarcoma
1
KRAS p.G12C Mutant Advanced Solid Tumors
1
Hematologic Neoplasms
1
Healthy Adult Participants
1
Glioma
1
Gastrointestinal Stromal Tumors
1
Colorectal Neoplasms
1
Central Nervous System Neoplasms
1
Cancer Pain
1
Interventions
enzalutamide
94
Magnetic Resonance Spectroscopy
85
Specimen Handling
66
Prednisone
64
Androgen Antagonists
59
Abiraterone Acetate
58
apalutamide
56
Radiosurgery
52
darolutamide
48
Radiotherapy
47
Leuprolide
47
abiraterone
45
Docetaxel
42
Pluvicto
32
Biopsy
31
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
30
Radiation
30
relugolix
28
Surveys and Questionnaires
28
gallium 68 PSMA-11
26
Standard of Care
26
pembrolizumab
25
Goserelin
25
Triptorelin Pamoate
24
Gonadotropin-Releasing Hormone
23
bicalutamide
22
Brachytherapy
21
Carboplatin
20
cabazitaxel
19
X-Rays
19
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostatic Neoplasms
×
Midazolam
×
1 year
×
Clear all
NCT04557449
2025-10-01
CDK4i
Pfizer
Phase 2
Active not recruiting
362 enrolled